3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
88
Gynecologic
3
Thoracic
2
Sarcoma
2
Head & Neck
2
Genitourinary
2
Breast
2
Conditions
Breast Neoplasms
22
Triple Negative Breast Neoplasms
6
Stomach Neoplasms
6
Neoplasm Metastasis
6
Pancreatic Neoplasms
5
Ovarian Neoplasms
5
Colorectal Neoplasms
4
Carcinoma, Renal Cell
4
Carcinoma, Non-Small-Cell Lung
4
Squamous Cell Carcinoma of Head and Neck
3
Prostatic Neoplasms
3
Melanoma
3
Colonic Neoplasms
3
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Multiple Myeloma
2
Hematologic Neoplasms
2
Fallopian Tube Neoplasms
2
Esophageal Neoplasms
2
Thrombocytosis
1
Small Cell Lung Carcinoma
1
Rectal Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Peritoneal Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Interventions
pembrolizumab
18
Trastuzumab
7
Docetaxel
7
Paclitaxel
6
Magnetic Resonance Spectroscopy
5
Taxes
4
Drug Therapy
4
Carboplatin
4
Specimen Handling
3
Psychiatric Rehabilitation
3
Polymerase Chain Reaction
3
Nivolumab
3
Injections
3
Fluorouracil
3
Fluorodeoxyglucose F18
3
Cyclophosphamide
3
Cisplatin
3
Capecitabine
3
Biopsy
3
poly ICLC
2
fludarabine
2
durvalumab
2
belinostat
2
atezolizumab
2
Radiotherapy
2
Oxaliplatin
2
Leucovorin
2
Lapatinib
2
Irinotecan
2
Interleukin-12
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Esophageal Neoplasms
×
Oxaliplatin
×
Breast
×
Clear all
NCT05891171
2026-03-31
ARC-25
Arcus Biosciences, Inc.
Phase 1
Active not recruiting
40 enrolled
NCT05007106
2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2
Completed
613 enrolled